Eagle Pharmaceuticals (EGRX) Reports In-Line Q4 EPS

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $1.00, in-line with the analyst estimate of $1.00. Revenue for the quarter came in at $46.8 million versus the consensus estimate of $52.91 million.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• SanDisk upgraded at JPMorgan after investor day; shares climb
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15